Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rintatolimod by AIM ImmunoTech for Melanoma: Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Rintatolimod by AIM ImmunoTech for Peritoneal Cancer: Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Rintatolimod by AIM ImmunoTech for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to...
Rintatolimod by AIM ImmunoTech for Epithelial Ovarian Cancer: Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Rintatolimod by AIM ImmunoTech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Rintatolimod by AIM ImmunoTech for Melanoma: Likelihood of Approval
Rintatolimod is under clinical development by AIM ImmunoTech and currently in Phase II for Melanoma. According to GlobalData, Phase II...